👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Kno2 and Pennant Group partner for healthcare innovation

Published 12/17/2024, 11:08 AM
PNTG
-

BOISE, Idaho - Kno2, a leader in healthcare communication technology, has announced a partnership with The Pennant Group, Inc. (NASDAQ: PNTG), a nearly $1 billion market cap healthcare services provider showing impressive 112% year-to-date returns, aimed at advancing patient care in home settings through improved data interoperability. According to InvestingPro data, Pennant Group has demonstrated strong momentum with revenue growth of 24.58% over the last twelve months. The collaboration, announced today, will see Pennant Group join Kno2's Qualified Health Information Network (QHIN), enhancing the exchange of health information across Pennant's network of home health, hospice, and senior living companies.

Therasa Bell, Kno2's president and co-founder, expressed enthusiasm about the integration, highlighting the shared goal of streamlining care delivery and improving clinical outcomes. The partnership is set to address the growing demand for at-home post-acute care, which has been intensified by an aging population and the shift of care services to home environments.

Pennant Group, through its independent operating subsidiaries, will utilize Kno2's healthcare communication infrastructure to foster automation and efficiency, with the goal of enhancing clinical operations and patient health outcomes. John Gochnour, Pennant's COO, sees the partnership as a significant step in their commitment to exceptional care delivery.

The integration with Kno2's Communication API is expected to bolster care coordination, patient safety, and support for value-based care initiatives. Pennant's CIO, Bryant Saxon, emphasized the importance of quick access to critical patient information, reducing administrative burdens, and allowing agencies to focus on care quality.

Kno2 continues to expand its reach in healthcare interoperability, connecting providers, payers, and patients. The addition of The Pennant Group to its QHIN is a testament to Kno2's dedication to enhancing connectivity within the healthcare ecosystem and addressing the industry's major challenges. With a robust current ratio of 1.12 and strong operational metrics, Pennant Group maintains a solid foundation for future growth. Detailed analysis and comprehensive research reports are available through InvestingPro, offering investors deep insights into the company's performance and potential.

This partnership is based on a press release statement and reflects Kno2's ongoing efforts to lead the future of healthcare communication by facilitating the sharing of information across the continuum of care.

In other recent news, The Pennant Group has reported robust growth for Q3 2024, with total revenue reaching $180.7 million, a 28.9% increase from the previous year. Adjusted earnings per share also saw a significant increase of 30% to $0.26. The company's Home Health and Hospice segment, as well as the Senior Living segment, were key drivers of this growth. These recent developments have led Pennant to raise its full-year guidance, forecasting adjusted revenue between $665.3 million and $706.5 million.

Pennant's growth was further propelled by acquisitions, including three Senior Living communities in Northern Wisconsin and the Washington and Idaho assets of Signature Healthcare at Home. In addition to these acquisitions, Pennant is set to close on the Oregon assets of Signature Healthcare at Home on January 1, 2025. The company continues to maintain a strong pipeline of acquisition opportunities, focusing on operational integration and clinical outcomes.

Despite facing challenges such as rising labor costs and flat Medicare reimbursement rates, Pennant remains well-positioned for future growth, with zero debt and a strong capital position. The company's operating margin improved significantly from 4.6% in Q3 2022 to 9.8% in Q3 2024. As part of Pennant's strategic growth plan, over 60 new CEOs are currently in training under the company's leadership development initiative.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.